

**Technology Advisory Committee A Interests Register**  
**Tirzepatide for managing overweight and obesity [ID6179]**  
**Publication Date: 23/12/2024**

Name	Role with NICE	Type of interest	Description of interest	Interest Declared	Comments
Becky Pennington	TAC A Member	Direct - Financial	Becky has signed a CDA for a potential project related to carers' HRQoL in Alzheimer's, but has not received any materials, contract or payment from Eli Lilly. If the project goes ahead, she would receive payment as private consultancy.	16/07/2024	It was agreed that Becky's declaration would not prevent her from participating in discussions on this appraisal
Dr Matthew Capehorn	Clinical Expert	Direct financial interest	Received research funding from Lilly, Novo Nordisk, and Boehringer in the last 12m together with honoraria for speaking for these companies and attending advisory board meetings. Matthew has also benefitted from funding to attend conferences.	07/08/2024 09/04/2024	It was agreed that Matthew's declarations would not prevent him from providing expert advice to the committee.
Sarah Le Brocq	Patient Expert	Direct – financial	Received honorarium payments for speaking events and training from Novo Nordisk.  Lilly have supported AAO as a corporate sponsorship member for the past 12 months.  Sarah received honorarium payments for speaking events and training from Novo NordiskSarah delivered a presentation to Eli Lilly internal commercial team, of her	07/08/2024 09/04/2024 16/01/2024 06/07/2023	It was agreed that Sarah's declarations would not prevent her from providing expert advice to the committee.

		Direct – non financial	<p>lived experience of living with obesity. To help educate the commercial team on the realities of obesity. She was paid an honorarium for her presentation. This took place on 16 January 2024.</p> <p>Sarah sits on the strategic council for the APPG for obesity</p> <p>Sarah is a Trustee at ASO</p> <p>Sarah is a member of the NHSE National Obesity Audit steering group</p>		
Dr Dimitris Papamargaritis	Clinical Expert	Direct – financial	<p>Novo Nordisk: Dimitris received honoraria for educational events and research grant support. He was co-investigator for an investigator initiated clinical trial funded by Novo Nordisk between 11/2017 and 12/2022 (<a href="https://classic.clinicaltrials.gov/ct2/show/NCT03036800">https://classic.clinicaltrials.gov/ct2/show/NCT03036800</a>). The study assessed the clinical effectiveness of liraglutide 3mg in Tier 3 weight management services when used with a targeted prescribing pathway with multiple stopping rules compared to standard care in Tier 3 weight management services.</p> <p>Academy of Medical Sciences/ Diabetes UK: Dimitris received research grant support (£29,944) between 06/2019 and 06/2022.</p> <p>Health Education East Midlands: Dimitris received research grant support (£9,985) between 02/2020 and 08/2022.</p>	<p>07/08/2024</p> <p>09/04/2024</p> <p>03/07/2023</p>	It was agreed that Dimitris' declarations would not prevent him from providing expert advice to the committee.

		Direct – non financial	<p>Trustee of the Association for the Study of Obesity (08/12/2022)</p> <p>Member of the Academic subcommittee for the Association of British Clinical Diabetologists (08/06/2021)</p> <p>Member of the Research Grant subcommittee for the Association of British Clinical Diabetologists (08/06/2021)</p> <p>Co-founder of the Diabetes Update course, organised by the Association of British Clinical Diabetologists</p> <p>Contributed to ASO comments submission at the scoping consultation invitation for ID6179 (tirzepatide for people with overweight/obesity)</p>		
		Indirect	<p>Working in Leicester Diabetes Centre where we host a national patient recruitment centre and multiple studies with new obesity and diabetes pharmacotherapies (including tirzepatide and cagri-sema) are taking place with principal investigator Prof Melanie Davies.</p>		